Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The Company’s lead product candidate, AR-13324, is the first of a new dual action drug class that reduces the eye’s fluid inflow while also increasing fluid outflow through the trabecular meshwork, which is the eye’s main fluid drain, all in a highly effective single drop per day. Aerie’s PG324 fixed combination of AR-13324 with latanoprost is a first-in-class glaucoma therapy to lower intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains. This product candidate offers the convenience of two drugs in one eye drop.

Type
Public
HQ
Irvine, US
Founded
2005
Size (employees)
70 (est)
Aerie Pharmaceuticals was founded in 2005 and is headquartered in Irvine, US

Key People at Aerie Pharmaceuticals

Richard J. Rubino

Richard J. Rubino

Chief Financial Officer
Casey C. Kopczynski

Casey C. Kopczynski

Chief Research Officer and Co-Founder
Thomas A. Mitro

Thomas A. Mitro

President and Chief Operating Officer
Gerald D. Cagle

Gerald D. Cagle

Independent Director
Murray Goldberg

Murray Goldberg

Member of the Board of Directors

Aerie Pharmaceuticals Office Locations

Aerie Pharmaceuticals has offices in Irvine, Bedminster Township, Durham and Dublin
Irvine, US (HQ)
2030 Main St
Dublin, IE
28 32 Pembroke Street
Durham, US
4301 Emperor Blvd
Bedminster Township, US
135 Us 206

Aerie Pharmaceuticals Data and Metrics

Aerie Pharmaceuticals Financial Metrics

USD

Net income (FY, 2016)

(99.1 m)

EBIT (FY, 2016)

(96.9 m)

Market capitalization (21-Jul-2017)

2 b

Cash (31-Dec-2016)

197.9 m
Aerie Pharmaceuticals's current market capitalization is $2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

(52.4 m)

General and administrative expense

(44.5 m)

Operating expense total

(96.9 m)

EBIT

(96.9 m)

Pre tax profit

(98.9 m)

Income tax expense

(193 k)

Net Income

(31.1 m)(48.1 m)(74.4 m)(99.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

R&D expense

(10.6 m)(9.9 m)(12.3 m)(13.3 m)(12.7 m)

General and administrative expense

(7.5 m)(7.5 m)(9.8 m)(9.4 m)(10.6 m)

Operating expense total

(18.1 m)(17.4 m)(22.1 m)(22.7 m)(23.3 m)

EBIT

(18.1 m)(17.4 m)(22.1 m)(22.7 m)(23.3 m)

Pre tax profit

(18.6 m)(17.9 m)(22.7 m)(23.2 m)(23.8 m)

Income tax expense

(152 k)(72 k)(46 k)(47 k)(39 k)

Net Income

(18.5 m)(31.6 m)(17.2 m)(36 m)(54 m)(22.7 m)(45.9 m)(69.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

69.6 m85.6 m91.1 m197.9 m

Accounts Receivable

399 m

Inventories

618 k1.1 m1.9 m4 m

Current Assets

70.3 m141 m138.4 m237.7 m

Total Assets

70.5 m161.1 m159.1 m248.3 m

Accounts Payable

3.5 m551 k551 k551 k

Current Liabilities

3.5 m8.9 m17.1 m19.4 m

Total Liabilities

142.9 m

Additional Paid-in Capital

162 m171.3 m236.5 m422 m

Retained Earnings

(143.2 m)(217.6 m)(316.6 m)

Total Equity

67 m18.8 m105.3 m

Financial Leverage

1.1 x8.5 x2.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

27.9 m148.9 m113.5 m100.9 m106.9 m74.3 m58.5 m211.9 m

Current Assets

57.3 m171.7 m171 m159.9 m156.6 m120.7 m108.2 m256.5 m

Total Assets

57.7 m173.3 m195.2 m176.3 m175.2 m139.2 m120.1 m265.9 m

Accounts Payable

4.8 m7 m21.9 m17.7 m18 m15.5 m13.6 m13.5 m

Current Liabilities

4.8 m7 m22.4 m18.3 m18.5 m16 m14.1 m14.1 m

Additional Paid-in Capital

166.4 m168.8 m209.1 m213.1 m229.7 m240.2 m246.1 m415.6 m

Retained Earnings

(160.4 m)(179.2 m)(197.2 m)(240.3 m)(263.5 m)(287.3 m)

Total Equity

52.9 m42.2 m33.9 m32.5 m128.4 m

Financial Leverage

1.1 x4.1 x5.2 x5.4 x2.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(31.1 m)(48.1 m)(74.4 m)(99.1 m)

Depreciation and Amortization

64 k73 k252 k970 k

Accounts Payable

2 m551 k

Cash From Operating Activities

(16.4 m)(33.7 m)(55.7 m)(79.8 m)

Cash From Investing Activities

(63 k)(73.3 m)9.4 m18.1 m

Cash From Financing Activities

83.2 m123 m51.8 m168.6 m

Interest Paid

2.2 m2.2 m

Income Taxes Paid

600 k1.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(18.5 m)(31.6 m)(17.2 m)(36 m)(54 m)(22.7 m)(45.9 m)(69.7 m)

Depreciation and Amortization

31 k50 k24 k60 k102 k223 k457 k702 k

Accounts Payable

1.4 m2.3 m(12 k)(6 k)2.4 m(6 k)(6 k)

Cash From Operating Activities

(12.9 m)(22.4 m)(13.3 m)(29.6 m)(41.5 m)(19.4 m)(39.8 m)(61 m)

Cash From Investing Activities

(28.9 m)(22.6 m)6.1 m9.3 m14.4 m2.4 m5.1 m14 m

Cash From Financing Activities

74 k124.2 m35.1 m35.6 m48.5 m128 k2.2 m167.9 m

Interest Paid

551 k1.1 m1.6 m551 k1.1 m1.6 m

Income Taxes Paid

469 k600 k1.8 m1.8 m1.8 m
Y, 2016

Financial Leverage

2.4 x

Aerie Pharmaceuticals Market Value History

Aerie Pharmaceuticals Company Life and Culture

You may also be interested in